

DES In-stent Restenosis

Roxana Mehran, MD

Columbia University Medical Center
The Cardiovascular Research Foundation



CARDIOVASCULAR RESEARCH
FOUNDATION



COLUMBIA UNIVERSITY
MEDICAL CENTER

DES Restenosis

- *Mechanisms*
- Predictors
- Morphological patterns
- Therapy approach



Mechanisms of DES Restenosis

- ***Biological factors***

- Drug resistance

- Hypersensitivity

- ***Mechanical factors***

- Non uniform stent strut distribution

- Stent fractures

- Polymer peeling

- Non uniform drug deposition

- ***Technical factors***


- Incomplete stent expansion

- Stent gaps or “misses” (uncovered lesion segments)

- Barotrauma to unstented segments




DES fractures



Stent Fracture Analysis




Review of Adverse Event Reports submitted to
Cordis between August 2003 - July 2006

Follow-up findings



Technical factors

Stent underexpansion




Technical factors

Stent underexpansion


Post-Procedure MSA and Binary Restenosis (sensitivity and specificity curves)

Cypher



Sonoda S. et al. J Am Coll Cardiol 2004;43:1959-63


Taxus




Weissman N. TCT 2006

Technical factors

Gap



Incomplete stent coverage



Stent edge restenosis is frequently associated with local trauma outside the stent. In-stent restenosis occurs as a localized lesion, commonly associated with a discontinuity in stent coverage.

DES Restenosis

- Mechanisms
- *Predictors*
- Morphological patterns
- Therapy approach



Independent predictors of TLR after DES implantation

Randomized trials (on label)

SES arm in SIRIUS

- ✓ Post procedure in-stent MLD
- ✓ Total implanted stent length

Odds ratio

0.1840

1.0270

PES arm in TAXUS IV

- ✓ No study stents implanted
- ✓ No prior MI
- ✓ Female gender
- ✓ Lesion length

Hazard ratio (95% CI)

5.86 (1.36 - 25.27)

3.70 (1.11 – 12.50)

2.33 (1.08 – 5.00)

1.05 (1.01 – 1.10)



Independent predictors of DES restenosis

Registries (including off-label)

Rotterdam (Circulation. 2004)

- ✓ In-stent restenosis lesion
- ✓ Ostial lesions
- ✓ DM
- ✓ Vessel size
- ✓ LAD

Munich (Circulation. 2006)

- ✓ Vessel size
- ✓ Final Diameter stenosis
- ✓ DES type

Seoul (Am J Cardiol. 2006)

- ✓ DES type
- ✓ Final MLD
- ✓ Lesion length

Washington (ACC. 2007)

- ✓ Age
- ✓ Hypertension
- ✓ Procedural length
- ✓ Lack of IVUS guidance
- ✓ Total stented length

Milan (AHA. 2006)

- ✓ DM
- ✓ Unstable angina
- ✓ Reference vessel diameter
- ✓ Number of stents per lesion



DES Restenosis

- Mechanisms
- Predictors
- *Morphological patterns*
- Therapy approach
- « Delayed » restenosis



Morphological Patterns of DES In-Stent Restenosis Lesions

SIRIUS	Sirolimus (n=31)	Control (n=128)	P-value
I - focal	87%	42%	<0.001
II/III – diffuse or proliferative	6.5%	50%	<0.001
IV - total occlusion	6.5%	8%	0.895
TAXUS IV	Paclitaxel (n=16)	Control (n=65)	P-value
I - focal	63%	31%	<0.001
II/III – diffuse or proliferative	24%	66%	<0.001
IV - total occlusion	13%	3%	0.245





Patterns of In-Stent Restenosis

Cypher vs Taxus



Milan

Corbett SJ. et al.
Eur Heart J 2006



Seoul

Park CB. et al.
AHA 2006




■ Focal
 ■ Diffuse
 ■ Proliferative
 ■ Occlusive



Patterns of In-Stent Restenosis

Milan experience




DES Restenosis

- Mechanisms
- Predictors
- Morphological patterns
- *Therapy approach*



Conventional therapies vs SES for DES Failures

6-month angiographic outcomes





SES vs PES for SES Failures

Multicenter Registry in Asia


Restenosis @ 1 year

TLR @ 1 year




Same DES vs other DES vs. POBA for DES Failures

Does the switch therapy work?




Same DES vs other DES vs. other treatment for DES Failures

Does the switch therapy work?




Same DES vs other DES vs other treatment for DES Failures

Does the switch therapy work?



Do patterns of in-stent restenosis predict outcomes in the DES era?

QCA data @ 9 months



Current therapeutic options according to potential mechanisms of DES restenosis

Type of restenosis	Potential mechanisms	Treatment options
Focal in-stent	Underexpansion	BA
	Fracture	DES, BA
	Local vessel biology	DES, BA, atherectomy
	Heterogeneous drug distribution	DES, BA, atherectomy
Focal at stent edge	Geographic miss	DES
	Plaque progression	DES
Diffuse in-stent	Vessel biology / Drug resistance	Different DES, CABG
Proliferative	Vessel biology / Drug resistance	Different DES, CABG

DES Restenosis

Summary

- Restenosis after DES still occurs and at a disturbing frequency in the highest risk lesion/patient subsets.
- Underlying mechanism of DES restenosis involve a complex interplay of biological, mechanical, and technical (operator-dependent) factors.
- Strut fractures are more frequent than previously suspected, occurring most commonly at the edge of an overlap segment and they have been implicated in many clinical events, including restenosis, thrombosis, and aneurysm formation .



DES Restenosis

Summary

- **The morphologic patterns of DES restenosis are different from BMS, favoring a more focal and easily treated pattern with expected improved clinical outcomes.**
- **The treatment of DES restenosis is based on appreciation of underlying mechanisms and can vary from simple POBA, to DES when appropriate, to CABG in the most extreme cases.**
- **Late DES restenosis remains an infrequent clinical event, despite the differing healing patterns relative to BMS.**